Our collaborators
The Institute of Cancer Research collaborates with industrial, academic and hospital partners over a range of projects – from drug discovery programmes and biomarker studies, to the development of high intensity focussed ultrasound for the treatment of cancer.
Some of our recent collaborations have included:
Astex – a 3.5-year drug discovery collaboration aimed at identifying a preclinical candidate which inhibits the molecule MMSET.
AstraZeneca – a range of programmes and projects under a strategic alliance
BACIT – co-investment alongside Sareum and the CRT Pioneer Fund in the Chk1 drug development programme
CRT Pioneer Fund – a series of 4 collaboration and licence agreements on drug discovery programme
Domainex – providing chemistry support on a 5-year drug discovery collaboration funded by the Wellcome Trust
Elekta – a range of projects in the field of radiotherapy and imaging
Enzon pharmaceuticals – a biomarker collaboration
Horizon – collaboration to identify synthetic lethal cancer targets using Horizon’s isogenic cell lines
Illumina, Inc. – collaborative development of a cancer susceptibility genetic screening panel – TruSight Cancer
Janssen – a 2.5-year drug discovery collaboration
Merck – a multi-programme drug discovery collaboration
Nuevolution – a drug discovery collaboration working on difficult to drug targets
Onyx – a clinical trial of a novel α-folate receptor-mediated thymidylate synthase inhibitor using a study drug that was developed at ICR
Phillips – A collaboration in the field of High Intensity Focused Ultrasound (HIFU) treatment aiming to evaluate and optimise novel applications of HIFU in the treatment of cancer
Ventana – a multi-program collaboration providing equipment and support for a number of projects
Other industrial collaborators include: Amgen, EMD Millipore, Genentech, GSK, Morphosys, Oncolytics, PreCOS, Roche, Sanofi Aventis, Symphogen and Teva.
